Literature DB >> 2564806

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

C Wright1, B Angus, S Nicholson, J R Sainsbury, J Cairns, W J Gullick, P Kelly, A L Harris, C H Horne.   

Abstract

Sections of formalin-fixed, paraffin-embedded tissue from 185 primary breast carcinomas were stained immunohistochemically using a polyclonal antibody against the c-erbB-2 oncoprotein. Positive staining, which is known to correlate with gene amplification, was associated with earlier relapse, shorter postrelapse survival, and shorter overall survival. Lymph node, epidermal growth factor receptor, and estrogen receptor status, tumor size, and histological grade also had prognostic significance but, applying multivariate analysis, only lymph node status was a more important predictor of relapse-free and overall survival than staining for the oncoprotein. Positive staining was correlated with negative estrogen receptor status and high histological grade, but there was no association with either lymph node or epidermal growth factor receptor status or tumor size. Expression of the c-erbB-2 oncoprotein appears to be an important independent indicator of prognosis in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564806

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  128 in total

1.  Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast.

Authors:  T Hasebe; S Sasaki; S Imoto; A Ochiai
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Immunohistochemical Detection of p53 and c-erbB-2 Proteins: Prognostic Significance in Operable Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

3.  erbB2 expression in breast and other human tumours.

Authors:  C Wright; K Prasad; T J Lennard
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

4.  c-erbB-2 oncogene product expression and prognosis in gastric carcinoma.

Authors:  D A Hilton; K P West
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

5.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

6.  Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Authors:  Liancheng Zhu; Salvatore Lopez; Stefania Bellone; Jonathan Black; Emiliano Cocco; Tiffany Zigras; Federica Predolini; Elena Bonazzoli; Beatrice Bussi; Zachary Stuhmer; Carlton L Schwab; Diana P English; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Tumour Biol       Date:  2015-02-11

7.  Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).

Authors:  Maria D Corte; Juan A Rodil; Julio Vázquez; Lucia García; Juan C Rodríguez; Miguel Bongera; José C Fernández; Luis O González; Ma Luz Lamelas; Maite Allende; José L García-Muñiz; Antonio Fueyo; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

8.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

Review 9.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.